Results 1 to 10 of about 2,703 (107)

Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis [PDF]

Cancer Medicine
Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection.
Anna Homeniuk, Amrit Sandhu, Leena Abdalla, Anas Atrash   +3 more
doaj   +2 more sources

Zanubrutinib-induced aseptic meningitis: a case report and literature review

Frontiers in Pharmacology, 2023
Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B cell malignancy treatment and is generally well tolerated in most patients. Zanubrutinib-induced aseptic meningitis is currently not reported.
Jinjun Yang, Lian Wang, Xiao Zhong, Chenlu Yang, Yu Wu   +4 more
doaj   +3 more sources

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

Cancer Medicine, 2023
Background We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present an updated pooled
Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu   +21 more
doaj   +2 more sources

Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-na¨ıve patients with chronic lymphocytic leukemia: a matchingadjusted indirect comparison [PDF]

Journal of Comparative Effectiveness Research
Aim: Fludarabine, cyclophosphamide and rituximab (FCR) is a first-line therapy for fit treatment-naive patients with chronic lymphocytic leukemia (CLL); however, its hematotoxicity and related infections necessitate more efficacious, safer treatments ...
Talha Munir, Lianne Barnieh, Leyla Mohseninejad, Sheng Xu, Milica Jevdjevic, Walter Bouwmeester, Keri Yang   +6 more
doaj   +2 more sources

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL [PDF]

Oncology and Therapy
Introduction There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL).
Daniel A. Ermann, Deborah M. Stephens, Xiaoliang Wang, Irene Varghese, Heidi De Souza, Caitlin Sheetz, Qianhong Fu, Gregory A. Maglinte, Rhys Williams, Erlene K. Seymour, Derrick van Beuge, Mazyar Shadman, Ryan Jacobs   +12 more
doaj   +2 more sources

Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy [PDF]

Blood Science
Anti-CD19 chimeric antigen receptor T cells (CAR T) still have many limitations, including insufficient clinical efficacy. Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor with higher drug potency, and it is not clear whether it
Hao Yao, Ling Qiu, Shi-Hui Ren, Dan Chen, Meng-Jiao Li, Bai-Tao Dou, Nan Zhang, Xiao Wang, Yi Su, Alex H. Chang, Fang-Yi Fan   +10 more
doaj   +2 more sources

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Frontiers in Immunology, 2022
IntroductionRelapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy.
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Wenbin Qian, Yun Liang   +9 more
doaj   +3 more sources

Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China [PDF]

Health Economics Review
Objective To evaluate the cost-effectiveness of zanubrutinib compared to ibrutinib in the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) from the perspective of the Chinese healthcare system. Methods A three-
Ying Liu, Wei Li, Xiaoxia Wei, Haijing Guan, Sheng Han   +4 more
doaj   +2 more sources

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma [PDF]

Blood Advances
: This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in ...
Tycel Phillips, Mengyang Di, Taavy A. Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene K. Seymour, Yucai Wang   +7 more
doaj   +2 more sources

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions

Frontiers in Oncology, 2023
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies.
Anna Wolska-Washer, Anna Wolska-Washer, Tadeusz Robak, Tadeusz Robak   +3 more
doaj   +1 more source